Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
uterine artery embolization, hysterectomy · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| uterine artery embolization | PROCEDURE | - |
| hysterectomy | PROCEDURE | - |
Inclusion Criteria: * Uterine fibroids * Menorrhagia * Scheduled for hysterectomy * Pre-menopausal Exclusion Criteria: * Childwish (planning to conceive) * Pregnancy * Suspected malignancy * Untreated pelvic inflammatory disease (PID) * Clotting disorders * Contrast fluid allergy * Presence of in...
Uterine artery embolization and hysterectomy are used for menorrhagia, or heavy menstrual bleeding, often associated with uterine fibroids. The Emmy Trial studied these procedures in women with menorrhagia, leiomyoma, and uterine neoplasms. The trial enrolled 120 female participants aged 18 years and older in the Netherlands.
Boston Scientific Corporation (ticker: BSX) is the developer of uterine artery embolization and hysterectomy. The company conducted the Emmy Trial, a Phase 3 study comparing these procedures for the treatment of menorrhagia and uterine fibroids.
Uterine artery embolization and hysterectomy are in Phase 3 clinical development. The Emmy Trial, a Phase 3 study, has been completed. The procedures remain investigational for the treatment of menorrhagia and are not stated to be FDA approved.
Uterine artery embolization and hysterectomy were studied in the Emmy Trial, registered as NCT00100191. This Phase 3 trial compared uterine artery embolization versus hysterectomy for uterine fibroids in women with menorrhagia. The trial enrolled 120 participants and has been completed.
Yes, uterine artery embolization is commonly abbreviated as UAE. The Emmy Trial, NCT00100191, compared uterine artery embolization (UAE) versus hysterectomy for uterine fibroids. Both procedures are used to treat menorrhagia and related uterine conditions.